# Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer

> **NCT07004712** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 46 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Adebelizumab combined with irinotecan liposome as second-line therapy

## Key facts

- **NCT ID:** NCT07004712
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2028-03-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07004712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07004712, "Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07004712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*